Craniectomy

PROCEDURE5 trials

Sponsors

Integra LifeSciences Corporation, MiMedx Group, Inc., Aarhus University Hospital, National Cheng-Kung University Hospital, University of Health Sciences Lahore

Conditions

Brain MetastasesGlioblastomaNSCLC Stage IVPosterior Fossa LesionScarringSurgery

Phase 1

Enhancing Optune Therapy With Targeted Craniectomy

CompletedNCT02893137

Aarhus University HospitalGlioblastoma

Start: 2016-10-01End: 2019-05-31Updated: 2019-11-27

Unknown Phase

Prospective, Multicenter Observational Study Evaluating the Long Term Safety of the Custombone Implant

CompletedNCT01824706

Integra LifeSciences CorporationSurgery

Start: 2012-12-01End: 2016-05-01Updated: 2018-07-02

Amniotic Membrane in Decompressive Craniectomy to Reduce Scarring

CompletedNCT02033824

MiMedx Group, Inc.Scarring

Start: 2014-04-30End: 2018-06-30Updated: 2018-08-23

Genomic Study in Non-small Cell Lung Cancer Brain Metastasis

CompletedNCT04745715

National Cheng-Kung University HospitalBrain Metastases, NSCLC Stage IV

Start: 2011-01-01End: 2022-10-31Updated: 2023-04-04

Comparison of Surgical Outcomes of Craniotomy and Craniectomy in Posterior Fossa Lesions

Not yet recruitingNCT06831695

University of Health Sciences LahorePosterior Fossa Lesion

Start: 2025-03-04End: 2026-03-31Target: 80Updated: 2025-02-18

Related Papers

Validating skullremodeling surgery configuration to enhance TTFields for first recurrence glioblastoma with computational modeling

WFNOS 2022 Abstract Book2022-01-01

Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial

Cancer Research2020-08-15

SURG-01. OPTIMALTTF-1: FINAL RESULTS OF A PHASE 1 STUDY: FIRST GLIOBLASTOMA RECURRENCE EXAMINING TARGETED SKULL REMODELING SURGERY TO ENHANCE TUMOR TREATING FIELDS STRENGTH

Neuro-Oncology2019-11-01

P05.03 OptimalTTF-1: Final results of a phase 1 study at first glioblastoma recurrence examining targeted craniotomy to enhance Tumor Treating Fields intensity

Neuro-Oncology2019-08-01

ACTR-43. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED SKULL REMODELING SURGERY TO MAXIMIZE TTFIELDS INTENSITY FOR RECURRENT GLIOBLASTOMA – INTERIM ANALYSIS AND SAFETY ASSESSMENT (OPTIMALTTF-1)

Neuro-Oncology2018-11-013 citations

P01.029 Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma - Interim analysis and safety assessment (OptimalTTF-1)

Neuro-Oncology2018-09-01

ACTR-54. OPEN-LABEL PHASE 1 CLINICAL TRIAL TESTING PERSONALIZED AND TARGETED INTERVENTION WITH SKULL REMODELLING SURGERY TO MAXIMIZE LEVELS OF TTFIELDS INTENSITY FOR HIGHER TREATMENT BENEFIT - THE OPTIMAL TTF STUDY

Neuro-Oncology2017-11-01